be the leader in the development and commercialization of novel
pharmaceutical products for pain management. The company has one
FDA-approved product, Zingo(TM) for the reduction of pain associated with
venous access procedures. The second product in the pipeline, Adlea, has
been shown to reduce pain after only a single administration for weeks to
months in multiple settings based on mid-stage clinical trials for
site-specific, moderate-to-severe pain. Anesiva is based in South San
Francisco, CA. For more information about Anesiva's leadership in the
development of products for pain management, and an overview of the
clinical challenges being addressed by its product candidates, go to
(1) Zempsky WT, Bean-Lijewski J, Kauffman RE et al. Needlefree Powder
Lidocaine Delivery System Provides Rapid Effective Analgesia for
Venipuncture or Cannulation Pain in Children: Randomized,
Double-Blind Comparison of Venipuncture and Venous Cannulation Pain
After Fast-Onset Needlefree Powder Lidocaine or Placebo Treatment
Trial. Pediatrics. 2008;121(5):1-9.
(2) Anesiva, Data on File.
(3) Wong DL and Baker CM. Pain in Children: Comparison of Assessment
Scales. Pediatric Nursing. 1988;14:9-17.
(4) Fradet C, McGrath PJ, Kay J, Adams S, Luke B. A prospective survey
of reactions to blood tests by children and adolescents. Pain.
(5) American Academy of Pediatrics Committee on Psychosocial Aspects of
Child and Family Health and American Pain Society Task Force on Pain
in Infants, Children, and Adolescents. The assessment and management
of acute pain in infants, children, and adolescents. Pediatrics.
(6) Bhargava R, Young K. Procedural pain management patterns in academic
pediatric emergency dPage: 1 2 3 4 5 Related medicine technology :1
. Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement2
. Anesiva Commences Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Bunionectomy3
. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults4
. Anesiva Defines Regulatory Pathway for Adlea with FDA5
. Anesiva Initiates Phase 2 Trial with Adlea(TM) for Pain Relief Following Total Hip Replacement Surgery6
. Anesiva Initiates New Phase 2 Trial of Adlea(TM) for Pain Relief Following Knee Replacement Surgery7
. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults8
. ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing9
. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Prevention of Diabetic Foot Infections10
. Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology11
. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)